A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects With Pancreatic Cancer
Clinical Application Study of Rejuvenated Tumor-Reactive T Cells in Pancreatic Cancer
A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects with Pancreatic Cancer
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Hao Jihui
- Telefonnummer: +86-02223340123
- E-Mail: haojihui@tjmuch.com
Studienorte
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China
- Rekrutierung
- Tianjin Medical University Cancer Institute & Hospital
-
Kontakt:
- Hao Jihui, MD
- Telefonnummer: +86-02223340123
- E-Mail: haojihui@tjmuch.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Informed Consent Form (ICF) .
- Aged 18 to 70 years (inclusive) at the time of signing the ICF.
- Cytology or pathology confirmed Patients with pancreatic tumors.
Cohort 1:
- The subject has undergone radical total resection of the primary tumor with curative intent, as determined by the investigator.
- Adjuvant chemotherapy completed, as determined by the investigator.
Cohort 2:
- Disease progression after prior standard systemic antitumor therapy for the current disease stage;
- Inability to continue standard therapy due to clinically significant and intolerable toxicities, as determined by the investigator, during prior standard treatment;
- No standard treatment option is currently available, tolerable, and expected to provide clinical benefit for the participant, based on current clinical practice and the investigator's judgment;
- For locally recurrent disease, radical surgical resection is deemed unsuitable by the investigator.
Cohort 3:
-
Patients receiving standard chemotherapy regimens include, but are not limited to:
- the oFOLFIRINOX regimen;
- gemcitabine combined with nab-paclitaxel; or
- other standard first-line or second-line chemotherapy regimens as determined by the investigator according to local clinical practice guidelines.
-
Patients receiving targeted therapy must meet all the following criteria:
- Molecular testing confirms a clearly actionable biomarker abnormality (including, but not limited to, BRCA1/2 mutations, KRAS G12C mutation, HER2 alterations, NTRK fusions, or MSI-H/dMMR status);
- The investigator determines that no contraindications exist for the proposed targeted therapy.
-
ECOG score of 0 ~1 .
-
Expected survival time is more than 12 weeks.
-
Negative blood pregnancy test for females of childbearing potential is required.
Exclusion Criteria:
- Patients with central nervous system (CNS) metastasis, leptomeningeal disease, or metastatic spinal cord compression; or a history of CNS disorders, including but not limited to epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, etc.
- History of bone marrow or organ transplantation;
- History of other primary malignancies;
- Hepatitis B surface antigen (HBsAg) positivity; With negative HBsAg but positive hepatitis B core antibody (HBcAb) ,and if peripheral blood hepatitis B virus (HBV) DNA positive; Hepatitis C virus (HCV) antibody positive and HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Both Treponema pallidum-specific and non-specific antibody tests are positive.
- Patients with a known allergy to any component of the study drugs.
- History of active tuberculosis infection within 1 year prior to screening (subjects with a history of active tuberculosis infection more than 1 year ago are eligible if, in the investigator's judgment, there is no current evidence of active tuberculosis).
- Concurrent or previous history of interstitial lung disease or interstitial pneumonia; presence of chronic lung disease or other respiratory conditions that significantly impair lung function.
- Diagnosis of active autoimmune disease or a history of autoimmune disease that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, psoriasis, etc.), or at risk of such conditions.
- Clinically significant thyroid dysfunction as assessed by the investigator.
- Any uncontrolled active infection requiring parenteral (IV) antibiotic, antiviral, or antifungal treatment at the time of signing the ICF or within 4 weeks before the first infusion.
- Clinically significant cardiovascular diseases.
- Insufficient bone marrow reserve or insufficient organ function.
- Female subjects who are pregnant or breastfeeding.
- Administration of attenuated or inactivated vaccines within 28 days before signing the ICF, or planned administration of such vaccines during the screening period.
- The investigator considers that the subject's complications or other conditions may affect compliance with the protocol or that the subject is unsuitable for participation in this study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Kohorte 1
|
Combination with Adjuvant Chemotherapy |
|
Experimental: Kohorte 2
|
GKPTZ-01 |
|
Experimental: Kohorte 3
|
Combination with Chemotherapy or Targeted Therapy |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Recurrence-Free Survival
Zeitfenster: 2 years
|
6 months RFS(recurrence-free survival) rate(cohort 1) |
2 years
|
|
Objective response rate
Zeitfenster: 2 years
|
Proportion of subjects achieving complete response (CR) and partial response (PR)(cohort 2&3) |
2 years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Disease Control Rate(DCR)
Zeitfenster: 2 years
|
Proportion of subjects achieving best response of CR, PR, or SD treated with GKPTZ-01 |
2 years
|
|
Duration of Response(DOR)
Zeitfenster: 2 years
|
Time from first documented evidence of confirmed CR or PR until the first documented evidence of disease progression or death, whichever occurs earlier |
2 years
|
|
Progression-free Survival(PFS)
Zeitfenster: 2 years
|
Time from GKPTZ-01 treatment to disease progression or death |
2 years
|
|
Overall survival(OS)
Zeitfenster: 2 years
|
Time from GKPTZ-01 treatment to death |
2 years
|
|
Adverse events
Zeitfenster: 2 years
|
The incidence and severity of AEs (Adverse Events) and SAEs (Serious Adverse Events). |
2 years
|
|
Patient Quality of Life
Zeitfenster: 2 years
|
EORTC(European Organisation for Research and Treatment of Cancer) QLG (Quality of Life Group)Core Questionnaire (EORTC QLQ-C30) |
2 years
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pharmacokinetic
Zeitfenster: 2 years
|
Levels of T-cell Receptor copies |
2 years
|
|
Biomarker
Zeitfenster: 2 years
|
Concentration levels of serum cytokines, tumor markers |
2 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Neubildungen nach Standort
- Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Neoplasmen der endokrinen Drüse
- Erkrankungen der Bauchspeicheldrüse
- Neoplasmen der Bauchspeicheldrüse
- Therapeutika
- Kombinierte Modalitätstherapie
- Arzneimitteltherapie
- Chemotherapie, adjuvant
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- GATEWAY
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .